TipRanks 3 Top Dividend Stocks With Growth Opportunity; Goldman Sachs Says ‘Buy’ Investing is all about finding profits, and investors have long seen two main paths toward that goal. Growth stocks, equities that will give a return based mainly on share price appreciation, are one route. The second route lies through dividend stocks. These are stocks that pay out a percentage of profits back to shareholders – a dividend, usually sent out quarterly. The payments vary widely, from less than… Source link
Read More »Stocks advance amid Yellen testimony, Goldman Sachs earnings top estimates
Stocks rose Tuesday as traders returned from a long holiday weekend in the U.S. and eyed signs of mounting support for significant fiscal stimulus out of Washington. Each of the three major indexes advanced, and the Nasdaq outperformed with a jump of more than 1%. Bank stocks were mostly higher after Dow-component Goldman Sachs (GS) posted fourth-quarter results that handily exceeded expectations, even as Bank of America’s (BAC) quarterly report largely disappointed. On Tuesday, the Senate… Source link
Read More »Rays advance to World Series, Astros eliminated with a bit of poetic justice
The man who sealed the World Series for the Houston Astros in 2017 just stopped them from making it back, halting a historic ALCS comeback and sending baseball’s villains home with a bit of poetic justice. And now it’s the Rays headed to their first World Series since 2008, winning Game 7 of the ALCS by the score of 4-2. Charlie Morton, part of that 2017 Astros team that cheated and won the World Series, was outstanding on the mound for the Rays, dominating his former team in what was his… Source link
Read More »Stock futures advance after new Moderna data stokes vaccine optimism
Stock futures opened higher Tuesday evening after newly published data from Moderna (MRNA) fueled hopes that a vaccine providing protection against Covid-19 would be developed in the relative near-term. Moderna’s vaccine produced neutralizing antibodies in all 45 patients included in an early-stage human safety trial, according to data published after market close by the peer-reviewed New England Journal of Medicine. The data built on earlier promising, but incomplete, results Moderna had… Source link
Read More »